FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Many companies are already undergoing trials for a possible cure to the ongoing COVID-19 pandemic. Aside from the developments made by Pfizer and Moderna in developing their respective vaccines, another pharmaceutical company has made progress.
UK pharmaceutical firm AstraZeneca has developed a COVID-19 antibody cocktail that can potentially protect the person from infection for up to 12 months. The drug, known as AZD7442, makes use of a different process in helping the body fight the virus compared to a regular vaccine. Late-stage trials of the drug are already underway and the firm has started recruiting international clinical trials involving 5,000 from both Europe and the United States.
AZD7442 relies on the prophylactic process which involves introducing new antibodies into the body to fight the disease instead of triggering the body to create them. The drug acts with monoclonal antibodies that mimic the body’s natural antibodies and this process has already been used to treat cancer patients. This will especially be beneficial for those with weak immune systems compared to simply being vaccines as their bodies have already been compromised from creating new antibodies. The trials began over the weekend in the UK, involving 1,000 participants in nine sites.
The firm announced that this antibody cocktail can potentially treat patients or be taken as a preventative medication especially to healthcare workers at the front lines. “These have been engineered specifically to have what we call a long half-life, so we think they can confer protection for at least six, but more likely closer to 12 months,” said the company’s executive vice president of biopharmaceuticals research and development Mene Pangalos.
As the world waits for vaccines and a cure for COVID-19, people are highly advised to adhere to public health and safety guidelines to slow the spread of the coronavirus. Video streaming platform YouTube recently clamped down on the right-wing media organization OANN from posting videos and live streaming for a week, after the organization shared a fake cure for the disease.
Aside from restricting uploads, YouTube has also demonetized the channel, citing that the OANN has repeatedly violated its misinformation guidelines especially related to COVID-19.
